Gundling Felix, Rathmayer Markus, Koller Lisa, Wilke Michael, Kircheis Gerald, Wedemeyer Heiner, Labenz Joachim, Albert Jörg, Schepp Wolfgang, Lerch Markus M
Klinik für Gastroenterologie, Hepatologie und Gastroenterologische Onkologie, Klinikum Bogenhausen, Städtisches Klinikum München GmbH.
inspiring health GmbH, München.
Z Gastroenterol. 2020 Apr;58(4):323-331. doi: 10.1055/a-1068-3138. Epub 2019 Dec 20.
Hepatic encephalopathy (HE) represents a frequent complication of liver cirrhosis with negative effects on patients' lives. The prevalence of clinical HE is estimated to be between 30-45 %. Regardless of its clinical and prognostic relevance HE is considered to be underdiagnosed.
Beyond a systematic analysis of mortality of HE, we investigated the economic impact and reimbursement situation for HE in patients with liver cirrhosis in Germany. For the retrospective analysis, anonymized data (2011-2015) concerning expenses and diagnoses (§ 21-4 KHEntgG) were obtained from 74 participating hospitals of the Diagnosis Related Groups (DRG) Project of the German Gastroenterological Association (DGVS). Furthermore, results were compared with case data from all German hospitals provided by the German Federal Authority on Statistics (Statistische Bundesamt (Destatis), Wiesbaden).
In participating hospitals 59 093 cases with liver cirrhosis were identified of which 14.6 % were coded as having HE. Hospital mortality was threefold increased compared to cirrhosis-patients without HE (20.9 versus 7.5 %). Cases with cirrhosis as well as the proportion with HE increased over time. Compared to all patients with cirrhosis, reimbursement for HE patients produced a deficit (of up to 634 € for HE grade 4).
Mortality is threefold increased in patients with cirrhosis when an additional HE is diagnosed. Hospitals participating in the DGVS-DRG-project coded 2 % more HE cases among their cirrhosis cases than the rest of hospitals either because of a selection bias for greater disease severity or because of better coding quality. At present, reimbursement for HE patients on the basis of F-DRG-system produced a deficit.
肝性脑病(HE)是肝硬化常见的并发症,对患者生活产生负面影响。临床HE的患病率估计在30%-45%之间。尽管其具有临床和预后相关性,但HE仍被认为诊断不足。
除了对HE死亡率进行系统分析外,我们还调查了德国肝硬化患者中HE的经济影响和报销情况。为进行回顾性分析,从德国胃肠病学协会(DGVS)诊断相关组(DRG)项目的74家参与医院获取了2011-2015年有关费用和诊断的匿名数据(《社会法典》第五编第21-4条)。此外,将结果与德国联邦统计局(威斯巴登统计局)提供的所有德国医院的病例数据进行了比较。
在参与医院中,共识别出59093例肝硬化病例,其中14.6%被编码为患有HE。与无HE的肝硬化患者相比,医院死亡率增加了两倍(20.9%对7.5%)。肝硬化病例以及HE病例的比例随时间增加。与所有肝硬化患者相比,HE患者的报销出现了赤字(4级HE最高可达634欧元)。
当诊断出额外的HE时,肝硬化患者的死亡率增加两倍。参与DGVS-DRG项目的医院在其肝硬化病例中编码的HE病例比其他医院多2%,这要么是因为对疾病严重程度的选择偏倚,要么是因为编码质量更好。目前,基于F-DRG系统对HE患者的报销出现了赤字。